ClinicalTrials.gg
Not yet recruitingNCT07249892Updated Nov 25, 2025

A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases

A Phase 1/2 interventional study of BPR-6023021 for injection in Metastatic Solid Tumors, sponsored by Chengdu Syncor Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Chengdu Syncor Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
195
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases

Read the detailed description

This study is a multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases. The study is divided into two parts: Phase I and Phase II. The Phase I study is the dose escalation phase. The primary objective is to assess the safety and tolerability of a single administration of BPR-6023021 and to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) based on the occurrence of Dose-Limiting Toxicities (DLTs) associated with BPR-6023021 (if the MTD cannot be determined).The Phase II study is the dose expansion phase. The primary objective is to explore the efficacy of BPR-6023021 at a selected dose level.

02

Conditions studied

  • Metastatic Solid Tumors

Keywords

  • BPR-6023021
  • Advanced Solid Tumors
  • Bone Metastases
03

In context

Lead sponsor

Chengdu Syncor Pharmaceutical Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age should be up to 18 years at the time of signing the form (ICF);
  2. The (ECOG) performance status score should be ≤ 1;
  3. The expected survival period should be ≥ 3 months
  4. Phase I and phase II: Subjects with advanced solid tumor bone diagnosed by histology or cytology; and the subjects have failed standard treatment, or have no standard treatment, or are intolerant or not applicable to standard treatment
  5. Before the first administration, a 99mTc-MDP bone scan diagnosed multiple bone metastases, and at least two site was confirmed by CT or MRI;
  6. Have adequate organ and bone marrow functions;
  7. For subjects with reproductive capacity, take effective medical measures during the study treatment and within 6 months after the last administration;
  8. The subjects voluntarily join this study, sign the informed consent form, and can comply with the visit and related procedures stipulated in the protocol.

Exclusion criteria

Exclusion Criteria

  1. The before the first administration of the study drug was insufficient.
  2. Previous received similar radionuclide internal irradiation treatment.
  3. Previous received or planned to receive during the study period semi-body external radiotherapy targeting bone .
  4. Known "super bone imaging".
  5. Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression.
  6. Any cardiovascular or cerebrovascular diseases or cardiovascular risk factors that may affect the treatment of the study drug.
  7. Poorly controlled diabetes and hypertension.
  8. The toxicity of previous anti-tumor treatment before the first administration has not recovered to ≤ 1 grade (evaluated based on v5.0) or has not reached the level specified in the inclusion/exclusion criteria.
  9. Had other malignant tumors within 5 years before the first administration.
  10. Subjects with severe and/or uncontrolled concomitant diseases.
  11. Active or active .
  12. (HIV) test positive or having a history of acquired immune deficiency syndrome (AIDS); known active syphilis infection.
  13. During the screening process before the first administration, the condition deteriorated rapidly, such as significant changes in the investigator's assessment of physical condition, etc.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Phase 1:Dose escalation

    5 dose levels of BPR-6023021 are tentatively planned for Phase 1

    Drug: BPR-6023021 for injection

  • Experimental
    Phase 2: RP2D Cohort

    Participants will receive BPR-6023021 for injection at the Recommended Phase 2 Dose (RP2D) determined from the Phase 1 dose escalation study.The dose of BPR-6023021 for injection in Phase 2 is selected based on the Phase 1 monotherapy dose escalation study.

    Drug: BPR-6023021 for injection

Interventions

  • DrugBPR-6023021 for injection

    BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: Up to 1 year

Secondary outcomes

  1. Dosimetry,including Maximum plasma concentration (Cmax) of BPR-6023021

    To collect the biological distribution of major tissues/organs and so on.

    Time frame: Through study completion, an average of 2 year

  2. Time to Radiographic Bone Progresion (TTRBP)

    Time from start of treatment to progression of bone lesion (PD) or death, whichever occurs first, during the study period

    Time frame: Through study completion, an average of 2 year

  3. Radiographic progression-free survival (rPFS)

    Time from start of treatment to progression of Disease (PD) or death, whichever occurs first

    Time frame: Through study completion, an average of 2 year

  4. Symptomatic skeletal event-free survival (SSE-FS)

    Time from start of treatment to the first occurrence of new SSE or death from any cause , whichever occurs first.

    Time frame: Through study completion, an average of 2 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The individual participant data (IPD) collected in this study are considered confidential commercial information of the sponsor. Therefore, they will not be shared publicly to protect intellectual property and maintain competitive advantage.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Jul 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 25, 2025
StartEst.
Nov 19, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Sep 6, 2027
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07249892
Lead sponsor
Chengdu Syncor Pharmaceutical Co., Ltd.
Collaborators
Beijing Quarkxia Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Nov 19, 2025 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Sep 6, 2027 (estimated)
Last update
Nov 25, 2025

Study contacts

Rui Dong
Contact
rui.dong@btyy.com
+8613158775185
Ruofei Tong
Contact
ruofei.tong@btyy.com
+86-18002098164
Yan Yang
study director · Chengdu Syncor Pharmaceutical Co., Ltd.
Wei Fan
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion